Paris, France

Francois Vallee

This inventor holds 1 USPTO granted patent. Top assignee: Sanofi-Aventis. Active years: 2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Francois Vallee. Retrieved from https://idiyas.com/inventor/francois-vallee

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 11.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2012

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations by Francois Vallee

Introduction

Francois Vallee is a notable inventor based in Paris, France. He has made significant contributions to the field of medicinal chemistry, particularly through his innovative work on fluorene derivatives.

Latest Patents

Vallee holds a patent for "Fluorene derivatives, compositions containing the same and use thereof as inhibitors of the protein chaperone HSP 90." This invention relates to compounds of a specific formula, wherein various components are defined, and it highlights their potential use as medicinal products.

Career Highlights

Francois Vallee is associated with Sanofi-Aventis, a leading global biopharmaceutical company. His work focuses on developing new therapeutic agents that can effectively target and inhibit specific proteins involved in various diseases.

Collaborations

Vallee has collaborated with notable colleagues, including Fabienne Thompson and Patrick Mailliet, to advance research and development in his field.

Conclusion

Francois Vallee's innovative work and patent contributions reflect his commitment to advancing medicinal chemistry and improving therapeutic options. His efforts continue to impact the pharmaceutical industry positively.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…